Candida-related denture stomatitis: A pilot study of the efficacy of an amorolfine antifungal varnish

International Journal of Prosthodontics

Volumn 18, Issue 1, 2005, Pages 55-59

  Milillo, Lucio ^a   Lo Muzio, Lorenzo ^b,e   Carlino, Paolo ^a   Serpico, Rosario ^a   Coccia, Ermina ^c   Scully, Crispian ^d  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; NYSTATIN;

ADULT; AGED; ARTICLE; BIOFILM; CANDIDA; DRUG EFFICACY; FUNGAL COLONIZATION; HUMAN; PILOT STUDY; SIDE EFFECT; SJOEGREN SYNDROME; STOMATITIS; THRUSH; TOOTH PROSTHESIS; VARNISH;

EID: 13444270494     PISSN: 08932174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Grimoud AM, Marty N, Bocquet H, Andrieu S, Lodter JP, Chabanon G. Colonization of the oral cavity by Candida species: Risk factors in long-term geriatric care. J Oral Sci 2003:45:51-55.
2. Darwazeh AM, Al-Refai S, Al-Mojaiwel S. Isolation of Candida species from the oral cavity and fingertips of complete denture wearers. J Prosthet Dent 2001;86:420-423.
3. Pires FR, Santos EB, Bonan PR, Almeida OP, Lopes MA. Denture stomatitis and salivary Candida in Brazilian edentulous patients. J Oral Rehabil 2002;29:1115-1119.
4. Kulak-Ozkan Y, Kazazoglu E, Arikan A. Oral hygiene habits, denture cleanliness, presence of yeasts and stomatitis in elderly people. J Oral Rehabil 2002;29:300-304.
5. Dar-Odeh NS, Shehabi AA. Oral candidosis in patients with removable dentures. Mycoses 2003;46:187-191.
6. Webb BC, Thomas CJ, Willcox MD, Harty DW, Knox KW. Candida-associated denture stomatitis. Aetiology and management: A review. Part 1. Factors influencing distribution of Candida species in the oral cavity. Aust Dent J 1998;43:45-50.
7. Webb BC, Thomas CJ, Willcox MD, Harty DW, Knox KW. Candida-associated denture stomatitis. Aetiology and management: A review. Part 2. Oral diseases caused by Candida species. Aust Dent J 1998;43:160-166.
8. Rossie K, Guggenheimer J. Oral candidiasis: Clinical manifestations, diagnosis, and treatment. Pract Periodontics Aesthet Dent 1997;9: 635-641.
9. Barbeau J, Seguin J, Goulet JP, et al. Reassessing the presence of Candida albicans in denture-related stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:51-59.
10. Budtz-Jorgensen E. Etiology, pathogenesis, therapy, and prophylaxis of oral yeast infections. Acta Odontol Scand 1990;48:61-69.
11. Wilson J. The aetiology, diagnosis and management of denture stomatitis. Br Dent J 1998;185:380-384.
12. Budtz-Jorgensen E. Histopathology, immunology, and serology of oral yeast infections. Diagnosis of oral candidosis. Acta Odontol Scand 1990;48:37-43.
13. Webb BC, Thomas CJ, Willcox MD, Harty DW, Knox KW. Candida-associated denture stomatitis. Aetiology and management: A review. Part 3. Treatment of oral candidosis. Aust Dent J 1998;43: 244-249.
14. Baillie GS, Douglas LJ. Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 1999;48:671-679.
15. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000;46:397-403.
16. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001;183:5385-5394.
17. Chandra J, Mukherjee PK, Leidich SD, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vivo. J Dent Res 2001;80:903-908.
18. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32:1249-1272.
19. Egusa H, Ellepola AN, Nikawa H, Hamada T, Samaranayake LP. Subtherapeutic exposure to polyene antimycotics elicits a post-antifungal effect (PAFE) and depresses the cell surface hydrophobicity of oral Candida albicans isolates. J Oral Pathol Med 2000;29: 206-213.
20. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995;39: 2128-2131.
21. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995;49: 103-120.
22. Denning DW, Evans EG, Kibbler CC, et al. Fungal nail disease: A guide to good practice (report of a working group of the British Society for Medical Mycology). Br Med J 1995;311:1277-1281.
23. Fiume MZ. Final report on the amended safety assessment of diisopropyl dimer dilinoleate, dicetearyl dimer dilinoleate, diisostearyl dimer dilinoleate, dioctyl dimer dilinoleate, dioctyldodecyl dimer dilinoleate, and ditridecyl dimerdilinoleate. Int J Toxicol 2003;22(suppl 2):45-61.
24. Axéll T, Simonsson T, Birkhed D, Rosenborg J, Edwardsson S. Evaluation of a simplified diagnostic aid (Oricult-N) for detection of oral candidoses. Scand J Dent Res 1985;93:52-55.
25. Ellepola AN, Samaranayake LP. Antimycotic agents in oral candidosis: An overview: 2. Treatment of oral candidosis. Dent Update 2000;27:165-174.
26. Ellepola AN, Samaranayake LP. Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 2000;11:172-198.
27. Butticaz G, Zulian GB, Preumont M, Budtz-Jorgensen E. Evaluation of a nystatin-containing mouth rinse for terminally ill patients in palliative care. J Palliat Care 2003;19:95-99.
28. Daniels TE. Evaluation, differential diagnosis, and treatment of xerostomia. J Rheumatol Suppl 2000;61:6-10.
29. Blomgren J, Berggren LJ, Jontell M. Fluconazole versus nystatin in the treatment of oral candidosis. Acta Odontol Scand 1998;56: 202-205.
30. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004;34:192-2000.
31. Maza JL, Elguezabal N, Prado C, Ellacuria J, Soler I, Ponton J. Candida albicans adherence to resin-composite restorative dental material: Influence of whole human saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:589-592.
32. San Millan R, Elguezabal N, Regulez P, Maragues MD, Quindos G, Ponton J. Effect of salivary secretory IgA on the adhesion of Candida albicans to polystyrene. Microbiology 2000;146:2105-2112.
33. Carlino P, Lang R, Budtz-Jorgensen E. Antifungal varnish in the treatment of denture stomatitis [in French]. J Biol Buccale 1992;20: 45-50.
34. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10:1-10.
35. Cross LJ, Bagg J, Wray D, Atchison T. A comparison of fluconazole and itraconazole in the management of denture stomatitis: A pilot study. J Dent 1998;26:657-664.
36. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992;17(suppl 1):41-43.
37. Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: Comparison of two nail lacquer formulations. Clin Exp Dermatol 1992;17(suppl 1):29-32.
38. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer-Realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol 1992;17(suppl 1):26-28.
39. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: Comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992;184(suppl 1):21-24.
40. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine 5% nail lacquer in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992;17(suppl 1):44-49.
41. Kaneko K, Aoki N, Hoki M, Yajima J, Kawana S, Hattori S. Allergic contact dermatitis from amorolfine cream. Contact Dermatitis 1997; 37:307.
42. Kramer P. Contact dermatitis from amorolfine-containing cream and nail lacquer. Contact Dermatitis 1996;34:145.